# SGRY earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SGRY) · [Earnings tab](https://www.lopjlb.com/stock/SGRY?tab=earnings)

Updated: 2026-08-10T08:13:33

Quarters analyzed: 8

## Cross-quarter narrative

Across the series of earnings calls, Surgery Partners moved from a period of strong top‑line momentum and margin expansion to a more mixed outlook. Early calls highlighted double‑digit revenue growth, modest EBITDA margin improvement and an active M&A pipeline, while later quarters showed a slowdown to low‑single‑digit growth and softened same‑facility volume. Margin expansion tapered off, stabilizing after initial gains. De‑novo facility roll‑outs, initially on‑track, began to encounter construction and regulatory delays, raising execution risk. The company’s M&A ambitions stayed robust, but timing uncertainty surfaced, especially as the strategic review progressed. Regulatory and tariff risks were a constant backdrop, and leverage pressure persisted with net‑debt/EBITDA hovering near 4x. New concerns emerged in Q3 2025, including a shift toward a higher Medicare mix, commercial payer compression, and volume slowdown, compounded by physician availability issues. Robotics deployment remained on‑track throughout, supporting the shift toward higher acuity services. Overall, the narrative shifts from accelerating growth to managing execution challenges and emerging payer‑mix pressures while maintaining focus on strategic initiatives.

## Latest CallCard · Q1

SGRY Q1 2026: revenue $811M, same-facility rev +4.4%, EBITDA $102M; weather hit case growth (0.6%); margin 12.6%; reaffirms FY guidance; portfolio optimization mid-2026 target; robotics and de novos drive acuity shift.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlights early progress, s

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** SGRY Q1 2026: revenue $811M, same-facility rev +4.4%, EBITDA $102M; weather hit case growth (0.6%); margin 12.6%; reaffirms FY guidance; portfolio optimization mid-2026 target; robotics and de novos drive acuity shift.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlights early progress, s
- **2025 Q4:** —
- **2025 Q3:** Surgery Partners posted 6.6% revenue growth and modest EBITDA expansion, but softened same‑facility volume and payer mix led to a lowered full‑year outlook and a focus on de‑novo builds and strategic divestitures.
- **2025 Q2:** Surgery Partners delivered Q2 revenue of $826M and adjusted EBITDA of $129M, reaffirmed FY guidance, highlighted organic growth, margin expansion, a strong M&A pipeline and de‑novo rollout while noting timing uncertainty on acquisitions and regulatory outlook.
- **2025 Q1:** SGRY Q1 2025: revenue $776M (+8%), adj EBITDA $104M (+7%), same-facility +5.2%; reaffirmed FY guidance; strong volume growth offset by mix-driven rate pressure; robust M&A/de novo pipeline; sufficient liquidity.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlights consistent execution of 
- **2024 Q4:** Surgery Partners reported record $3B revenue, 30bps margin expansion and strong organic growth, reaffirmed 2025 guidance while noting modest tariff and leverage pressures and low regulatory risk.
- **2024 Q3:** SGRY Q3: revenue +14%, same-facility +4.2%, EBITDA margin +100bps to 16.7%; total joints +53% in ASCs; raised full-year guidance; M&A active; hurricane impact marginal; free cash flow target dropped due to accelerated deal spend.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlighted doubl
- **2024 Q2:** —

## Theme arcs

- **Revenue growth** (deteriorating): Growth slowed from double‑digit to low single‑digit and then softened
- **EBITDA margin** (stable): Early margin expansion gave way to flat performance
- **M&A activity** (stable): Pipeline active throughout, but timing risk emerged
- **De‑novo expansion** (deteriorating): Initial on‑track status later hampered by construction/regulatory delays
- **Regulatory environment** (stable): Regulatory risk persisted across calls

## Guidance path

2024 Q2:vague → 2024 Q3:vague → 2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:maintained → 2025 Q3:lowered → 2025 Q4:vague → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/SGRY`